Consistent with the in vitro data, knockdown of DEK also suppressed the growth of Jurkat cell-derived tumors in mouse model, suggesting that DEK is a promising therapeutic target in T-ALL treatment. Here, DEK is linked to acute lymphoblastic leukemia.